Coram Healthcare and Homemedco, which benefit from cost-conscious hospitals’ rush to get patients home.
Schering-Plough and Upjohn. All signs point to more consolidation, and investors might catch some profits from the merger action.
Chiron and Amgen. “I think Wall Street has thrown in the towel in biotech,” he says. “That’s when I love to step in and buy.”
